Aortic Valve Disease
The Boston Scientific Next Generation Acurate Neo2™ Aortic Valve System Demonstrates Favorable Outcomes In Clinical Practice - September 10, 2018
A new study evaluating the safety and performance of the Boston Scientific ACURATE neo2™ Aortic Valve System, a next generation transcatheter aortic valve implantation (TAVI) system, demonstrated a high procedural...
Boston Scientific Prevails in U.K. Edwards Lifesciences Litigation- March 28, 2018
Boston Scientific Corporation (NYSE: BSX) today announced the U.K. Court of Appeal dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’ Sapien 3™ device infringes Boston Scientific patent EP (UK) 2 926 766 and that all claims of that patent are valid...
The Boston Scientific LOTUS™ Valve System demonstrated superior efficacy to CoreValve® in global REPRISE III trial at one year - May 16, 2017
Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated that...
Boston Scientific Closes Symetis Acquisition - May 16, 2017
Acquisition Expands Company’s Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease.
Boston Scientific Receives CE Mark For LOTUS Edge™ Valve System - Sep 19, 2016
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology.
Background information about the disease, therapeutic options and our technologyView all